ClinicalTrials.gg
CompletedNCT02362048KEYNOTE144Updated Oct 1, 2019Results posted

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

A Phase 2 interventional study of ACP-196 and ACP-196 in combination with pembrolizumab in Metastatic Pancreatic Cancer, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing pembrolizumab in Pancreatic Neoplasms — 5 open to participants now, 9 under way, 1 of them phase 3. pembrolizumab · Pancreatic Neoplasms.

Enrollment
7th of 20
77 · median 38
Started
2015
the only one that year
Phase 2
12 of 20
3 open now
Registered
4th of 20
by date

Among the 20 studies testing pembrolizumab in Pancreatic Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 2, and was the 4th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

5 of the 20 studies testing pembrolizumab in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing pembrolizumab in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • performance status of 0 or 1
  • or cytologically confirmed advanced pancreatic ductal adenocarcinoma that is unresectable or
  • Prior therapy with ≥ 1 systemic chemotherapy regimen for unresectable or metastatic pancreatic cancer or unwilling/unable to receive systemic chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Prior (other than pancreatic cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years.
  • Known central nervous system (CNS) and/or carcinomatous meningitis
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction
  • Breastfeeding or pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Experimental: Arm 1

    ACP-196 alone

    Drug: ACP-196

  • Experimental
    Experimental: Arm 2

    ACP-196 in combination with pembrolizumab

    Drug: ACP-196 in combination with pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Every 12 weeks for up to 2 years.

07

Results

Posted Oct 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneArm 1 - Acalabrutinib MonotherapyArm 2- Acalabrutinib+Pembrolizumab
Started3740
Enrolled3740
Received study medication3538
Discontinued study3740
Completed00
Not completed3740

Outcome measures

PrimaryNumber of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Every 12 weeks for up to 2 years.
Reported as:
Count of participants · Participants
Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.
ParticipantsArm 1 - Acalabrutinib MonotherapyArm 2- Acalabrutinib+Pembrolizumab
Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.03

Adverse events

Collected over AE collected time frame was From the date of the first dose of study drug, through the treatment phase, and within 30 days following the last dose of Acalabrutinib or within 90 days following the last dose of Pembrolizumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Acalabrutinib Monotherapy30/35 (85.7%)14/35 (40%)34/35 (97.1%)
Arm 2- Acalabrutinib+Pembrolizumab34/38 (89.5%)26/38 (68.4%)38/38 (100%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventArm 1 - Acalabrutinib MonotherapyArm 2- Acalabrutinib+Pembrolizumab
Abdominal PainGastrointestinal disorders1/355/38
CholangitisHepatobiliary disorders2/352/38
PneumoniaInfections and infestations2/351/38
HypotensionVascular disorders2/350/38
Atrial FibrillationCardiac disorders0/352/38
VomitingGastrointestinal disorders0/352/38
DyspnoeaRespiratory, thoracic and mediastinal disorders0/352/38
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/352/38
NauseaGastrointestinal disorders1/351/38
Duodenal UlcerGastrointestinal disorders1/350/38
Most frequent other events
Showing 10 of 79
Most frequent other events
EventArm 1 - Acalabrutinib MonotherapyArm 2- Acalabrutinib+Pembrolizumab
Abdominal PainGastrointestinal disorders10/3521/38
Decreased AppetiteMetabolism and nutrition disorders11/3518/38
FatigueGeneral disorders11/3516/38
VomitingGastrointestinal disorders6/3515/38
AnaemiaBlood and lymphatic system disorders12/3514/38
NauseaGastrointestinal disorders8/3514/38
ConstipationGastrointestinal disorders8/3513/38
HeadacheNervous system disorders11/3511/38
Oedema PeripheralGeneral disorders9/355/38
Abdominal DistensionGastrointestinal disorders5/359/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Monotherapy ArmCombination ArmTotal
<=18 years000
Between 18 and 65 years202343
>=65 years151530
Age, Continuous
Age, Continuous(Year)Monotherapy ArmCombination ArmTotal
Mean62.9 ± 8.1961.3 ± 10.9462.1 ± 9.69
Sex: Female, Male
Sex: Female, Male(Participants)Monotherapy ArmCombination ArmTotal
Female181937
Male171936
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monotherapy ArmCombination ArmTotal
Hispanic or Latino156
Not Hispanic or Latino343367
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monotherapy ArmCombination ArmTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American314
White293362
More than one race112
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(participants)Monotherapy ArmCombination ArmTotal
United States353873
08

Study locations

1 site
  • Houston, Texas, United States
09

References and documents

Publications

  • Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 Feb;8(1):e000587. doi: 10.1136/jitc-2020-000587. PubMed 32114502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Mar 2017, 22 months.

Results were first posted in Oct 2019, 2 years 7 months after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 22 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2015
First posted
Feb 12, 2015
StartActual
May 2015
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Results first posted
Oct 1, 2019
Last update
Oct 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02362048
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Feb 12, 2015
Start date
May 2015
Primary completion
Mar 2017
Completion
Mar 2017
Results posted
Oct 1, 2019
Last update
Oct 1, 2019

Study contacts

Acerta Clinical Trial
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Pembrolizumab

Start the discussion